The '''Thrombosis''' '''Lymphoma (ThroLy) predictive score''' is a multivariable model for assessing the probability of thromboembolic events in patients with lymphoma. (Multivariable models are those that incorporate multiple independent variables.)
== Characteristics == The ThroLy score was developed and published in 2016 by a group of physicians from Serbia and the United States.<ref name=":0">{{Cite journal|last1=Antic|first1=Darko|last2=Milic|first2=Natasa|last3=Nikolovski|first3=Srdjan|last4=Todorovic|first4=Milena|last5=Bila|first5=Jelena|last6=Djurdjevic|first6=Predrag|last7=Andjelic|first7=Bosko|last8=Djurasinovic|first8=Vladislava|last9=Sretenovic|first9=Aleksandra|last10=Vukovic|first10=Vojin|last11=Jelicic|first11=Jelena|date=October 2016|title=Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients: Multivariable Predictive Model|journal=American Journal of Hematology|language=en|volume=91|issue=10|pages=1014–1019|doi=10.1002/ajh.24466|pmid=27380861|s2cid=1724916|doi-access=free}}</ref> As a simple model, it was initially internally validated based on individual clinical and laboratory patient characteristics that identify lymphoma patients at risk for a thromboembolic event. Based on an investigation that was conducted on derivation and validation cohorts, it was determined that the variables independently associated with a risk of thromboembolism in lymphoma patients are: previous venous and/or arterial events; mediastinal involvement; a BMI greater than 30 kg/m<sup>2</sup>; reduced mobility; extra-nodal localization; neutropenia; and a hemoglobin level less than 100g/L.<ref name=":0" /><ref name=":1">{{Cite journal |last1=Abdel-Razeq |first1=Hikmat |last2=Ma'koseh |first2=Mohammad |last3=Mansour |first3=Asem |last4=Bater |first4=Rayan |last5=Amarin |first5=Rula |last6=Abufara |first6=Alaa |last7=Halahleh |first7=Khalid |last8=Manassra |first8=Mohammad |last9=Alrwashdeh |first9=Mohammad |last10=Almomani |first10=Mohammad |last11=Zmaily |first11=Mais |date=January 2021 |title=The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma |journal=Clinical and Applied Thrombosis/Hemostasis |language=en |volume=27 |page=107602962110459 |doi=10.1177/10760296211045908 |issn=1076-0296 |pmc=8642105 |pmid=34590497}}</ref> {| class="wikitable" |+ !Patient characteristics !Assigned score |- |Previous venous thromboembolic event |2 |- |Reduced mobility |1 |- |Previous acute myocardial infarction or stroke |2 |- |Obesity (BMI ≥ 30) |2 |- |Extranodal localization |1 |- |Mediastinal involvement |2 |- |Neutropenia |1 |- |Hemoglobin˂100g/L |1 |}
== Risk classification == Based on the risk score, patients with lymphoma can be classified into three different risk groups.<ref name=":1" /> {| class="wikitable" |+ !Risk group !ThroLy score |- |Low risk |0-1 |- |Intermediate risk |2-3 |- |High risk |≥4 |}
== Further validations == The ThroLy score considers some particular characteristics of lymphoma patients, such as extranodal localization and mediastinal involvement. In addition to having a strong positive predictive value, the score is not limited to either hospitalized or outpatient settings, and does not require non-routine laboratory analyses. ThroLy score has been validated by multiple studies and entered clinical practice in several medical centers.<ref>{{Cite journal |last1=Ma'koseh |first1=Mohammad |last2=Abufara |first2=Alaa |last3=Albaghdadi |first3=Dana |last4=Ghalayni |first4=Ruba |last5=Abdel-Razeq |first5=Sarah |last6=Alzughali |first6=Eman |last7=Abdel Rahman |first7=Fadwa |last8=Alhalaseh |first8=Yazan |last9=Halahleh |first9=Khalid |last10=Abdel-Razeq |first10=Hikmat |date=2024-01-12 |title=The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma |journal=Journal of Clinical Medicine |language=en |volume=13 |issue=2 |page=436 |doi=10.3390/jcm13020436 |doi-access=free |issn=2077-0383 |pmc=10816014 |pmid=38256570}}</ref><ref>{{Cite journal |last1=Sánchez Prieto |first1=Irene |last2=Gutiérrez Jomarrón |first2=Isabel |last3=Martínez Vázquez |first3=Celia |last4=Rodríguez Barquero |first4=Pedro |last5=Gili Herreros |first5=Paula |last6=García-Suárez |first6=Julio |date=2024-04-27 |title=Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma |url=https://link.springer.com/10.1007/s11239-024-02977-0 |journal=Journal of Thrombosis and Thrombolysis |language=en |doi=10.1007/s11239-024-02977-0 |issn=1573-742X|doi-access=free |pmc=11315779 }}</ref><ref>{{Cite journal |last1=Leviatan |first1=Ilona |last2=Ellis |first2=Martin H. |date=December 2023 |title=Use of direct oral anticoagulants in hematologic malignancies |url=https://linkinghub.elsevier.com/retrieve/pii/S2666572723000238 |journal=Thrombosis Update |language=en |volume=13 |article-number=100152 |doi=10.1016/j.tru.2023.100152|doi-access=free }}</ref> However, multiple validation studies are ongoing and the results of additional studies may be needed before it can be fully applicable in clinical practice worldwide; several validation studies have been performed, and several more are ongoing.<ref>{{Cite journal|last1=Rupa-Matysek|first1=Joanna|last2=Brzeźniakiewicz-Janus|first2=Katarzyna|last3=Gil|first3=Lidia|last4=Krasiński|first4=Zbigniew|last5=Komarnicki|first5=Mieczysław|date=July 2018|title=Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice|url= |journal=Cancer Medicine|language=en|volume=7|issue=7|pages=2868–2875|doi=10.1002/cam4.1540|pmc=6051175|pmid=29761831}}</ref><ref>{{Cite journal |last1=Antic |first1=Darko |last2=Milic |first2=Natasa |last3=Mihaljevic |first3=Biljana |last4=Cheson |first4=Bruce |last5=Narkhede |first5=Mayur |last6=Abdel-Razeq |first6=Hikmat |last7=Panovska |first7=Irina |last8=Trajkova |first8=Sanja |last9=Popova |first9=Marija |last10=Aurer |first10=Igor |last11=Boban |first11=Ana |date=November 29, 2018 |title=External Validation and Revision of Thrombosis Lymphoma /Throly/ Score |url=https://ashpublications.org/blood/article/132/Supplement%201/140/262535/External-Validation-and-Revision-of-Thrombosis |journal=Blood |language=en |volume=132 |issue=Supplement 1 |page=140 |doi=10.1182/blood-2018-99-115568 |issn=0006-4971 |doi-access=free|url-access=subscription }}</ref><ref>{{Cite journal |last1=Assanto |first1=Giovanni Manfredi |last2=Salvatori |first2=Martina |last3=Pontecorvo |first3=Sara |last4=Maiorana |first4=Gianluca |last5=Cenfra |first5=Natalia |last6=D'elia |first6=Gianna Maria |last7=Bianchi |first7=Maria Paola |last8=Annechini |first8=Giorgia |last9=Santoro |first9=Cristina Santoro |last10=Martelli |first10=Maurizio |last11=Tafuri |first11=Agostino |last12=Pulsoni |first12=Alessandro |last13=Del Giudice |first13=Ilaria |last14=Chistolini |first14=Antonio |date=August 2023 |title=S219: Predicting Thrombotic Risk in Patients with Hodgkin Lymphoma: A Multicentric Study of Throly and Khorana Risk Scores |url=https://journals.lww.com/hemasphere/Fulltext/2023/08003/S219__PREDICTING_THROMBOTIC_RISK_IN_PATIENTS_WITH.121.aspx |journal=HemaSphere |language=en-US |volume=7 |issue=S3 |pages=e700140a |doi=10.1097/01.HS9.0000967788.70014.0a |issn=2572-9241|pmc=10428474 }}</ref>
==References== {{Reflist}}
Category:Lymphoma